Background: Diabetes technologies—including continuous glucose monitoring (CGM), insulin pumps, and hybrid closed-loop systems—have profoundly transformed self-management in type 1 diabetes (T1D). While these technologies offer improved glycemic control and safety, their use in ultraendurance sports introduces specific cognitive, material, and organizational challenges that remain underexplored in digital health research. Objective: This study aimed to explore […]
Capricor sues partner Nippon Shinyaku in DMD therapy spat
Capricor has filed a lawsuit seeking to split from its commercial partner for Duchenne muscular dystrophy therapy, deramiocel, in the US.
‘Pharma, not really’: Top young AI talent shuns careers at big drugmakers
RIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a 33-year-old postdoctoral fellow at MIT and Harvard Medical School, is building …
Thematic Mapping and Evolution of Social Media Mining in Health Research: Hybrid Bibliometric Synthesis
Background: Social media platforms offer extensive data, as they are widely used globally. Social media mining (SMM) enables real-time monitoring of user-reported health information and serves as a supplement to traditional health data analytics. However, the rapid proliferation of literature has produced fragmentation, and a comprehensive knowledge map regarding SMM is lacking. Further, existing bibliometric […]
Eisai, Biogen face delay to subcutaneous Leqembi
Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer’s, viewed as a key growth driver.
Natalie Holles’ next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech
→ It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de los Pinos as CEO of …
Capricor sues Nippon Shinyaku over Duchenne drug ‘pricing flaw’ and launch prep
Capricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular dystrophy (DMD) that’s getting a second chance at …
J&J seeks to rewrite the script on depression treatment
A survey has found that most patients with depression have little hope of being free of their symptoms, and Johnson & Johnson aims to change that.
Windward raises $165m for TSLP drug, and other biofinancings
Recent biotech financings include nine-figure rounds for Windward Bio and Coultreon, with Vivacta, Kanvas, and Moleculent also raising funds.
Manufacturing hangover drives Daiichi Sankyo into the red
Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.
Here’s how technology transformed babymaking
Technology is changing the way we make babies. The pioneering work of the scientists who invented IVF led to the birth of the first “test tube baby” in 1978. We’ve come a long, long way since then. This week, I’ve been working on a piece about the cutting edge of IVF technologies and what’s coming […]
AbbVie’s Skyrizi beats out J&J’s Tremfya in in April drug ad spending leaderboard
After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the drug with the highest level of ad spending.